Moderna (MRNA, $183.74) seeks to pack 50% more vaccine in vials
Biotech company Moderna said it was seeking approval from regulators around the globe to pack 50 per cent more coronavirus vaccine into each of its vials, in order to boost current supply levels.
The company gave a statement after The New York Times first reported that the US Food and Drug Administration (FDA) had already given permission to it to increase the amount by 40 per cent.
A spokesperson said that the company was having discussions with the FDA and authorities in other countries, and the increased level of doses wouldn't require different vials to those currently in use.
“In order to better maximise resources as well as maximise opportunities to deliver more doses into each market faster, Moderna has proposed filling vials with up to 15 doses of vaccine versus the previous 10 doses," the spokesperson said in a statement to AFP. "Any resulting change would be subject to final approval from the various regulatory authorities. Implementation of any such changes would be expected to be completed in approximately a two- to three-month period," they said.
Momentum Indicator for MRNA turns positive, indicating new upward trend
MRNA saw its Momentum Indicator move above the 0 level on March 06, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MRNA's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on March 05, 2025. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where MRNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MRNA entered a downward trend on February 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.217) is normal, around the industry mean (11.662). P/E Ratio (0.000) is within average values for comparable stocks, (63.227). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (4.117) is also within normal values, averaging (241.648).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of transformative medicines for patients
Industry Biotechnology